Category: Providers

CMS Inaction on IRA-340B Conflicts May Drive ‘Manufacturer-Friendly’ Compliance Models

October 10, 2024 William Newton, Associate Editor/Senior Writer Views

CMS has not assumed responsibility for “deduplicating” discounts that arise between the 340B program and the IRA's Medicare drug price negotiations.

Federal regulators’ inaction on the 340B program’s interactions with Medicare drug price negotiations will likely lead drugmakers to pursue “manufacturer-friendly” [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Head of Drug Industry-Funded Think Tank Backs J&J’s Proposed Rebate Model, Slams Hospitals in Op-Ed

October 10, 2024 Shannon Young, Associate Editor/Senior Writer Views

Sally Pipes, the president and CEO of the drug-industry funded Pacific Research Institute, criticized pushback that led Johnson & Johnson to forgo its plans to implement a 340B rebate model in an Oct. 7 Forbes op-ed.

The leader of a right-leaning think tank that’s received funding from the drug industry criticized pushback that led Johnson & [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

CMS’ MDRP Final Rule May Impact 340B Covered Drugs, Attorneys Say

October 8, 2024 William Newton, Associate Editor/Senior Writer Views

CMS' recently-released MDRP final rule may affect 340B covered drugs and draw litigation.

A new federal regulation updating the definition of a covered outpatient drug could change the number of drugs covered under [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

CMS Finalizes Next Medicare Drug Negotiation Guidance Without Resolving Key Concerns of 340B Stakeholders

October 3, 2024 William Newton, Associate Editor/Senior Writer Views

The AHA raised concerns that October 2024 federal guidance on Medicare drug price negotiations may allow drugmakers to “wrongly justify fundamental changes to the 340B program.”

Federal regulators issued final guidance for the next round of Medicare drug price negotiations yesterday but did not propose remedies [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

340B Provider Groups, Key Federal Lawmaker Praise HRSA for Pressuring J&J to Drop 340B Rebate Proposal

October 1, 2024 William Newton, Associate Editor/Senior Writer Views

U.S. Rep. Abigail Spanberger (D-Va.) and multiple 340B provider groups applauded HRSA for its response on J&J's 340B rebate proposal.

Multiple 340B provider groups have applauded the federal government for threatening “strong” enforcement actions that led Johnson & Johnson (J&J) [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Kalderos Launches New Drug Discount Platform with 340B Rebate Capabilities as Lawsuit with HHS Remains Paused

October 1, 2024 William Newton, Associate Editor/Senior Writer Views

Kalderos announced a new drug discount platform that supports 340B rebate capabilities.

Drug industry vendor Kalderos last week launched a new drug discount platform with 340B rebate capabilities as its prior lawsuit [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

J&J Abandons 340B Rebate Due to HRSA’s Enforcement Threats But Defends Model in Letter to Agency

September 30, 2024 William Newton, Associate Editor/Senior Writer Views

J&J announced it will "forgo implementation" of its 340B rebate proposal due to enforcement threats from HRSA.

Johnson & Johnson (J&J) notified the Health Resources and Services Administration (HRSA) this morning that it will drop its 340B [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Sanofi Imposes New 340B Contract Pharmacy Rule in Arkansas Following Legal Deal with State

September 26, 2024 William Newton, Associate Editor/Senior Writer Views

Sanofi implemented a new 340B contract pharmacy rule for certain Arkansas hospitals.

Sanofi is requiring Arkansas hospitals to prove they legally own 340B-priced drugs until they are dispensed at contract pharmacies after [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

CMS Publishes Final Rule on Medicaid Rebates with Significant 340B Implications

September 24, 2024 William Newton, Associate Editor/Senior Writer Views

CMS released a final rule for Medicaid rebates with new identifiers and definitions that impact the 340B program.

Federal regulators last Friday finalized a highly anticipated rule for the Medicaid Drug Rebate Program (MDRP) with new identifiers and [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

AHA Op-Ed Takes Aim at ‘Big Pharma’s’ 340B Program Growth Rhetoric

September 24, 2024 Shannon Young, Associate Editor/Senior Writer Views

AHA officials penned a Medical Economics op-ed on “the truth behind growth of the 340B prescription drug program.”

A major hospital group recently hit back against the drug industry’s claims that hospital behavior has helped drive “out of [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Breaking News

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Site Footer Live